florbetaben F18 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 4818 | 902143-01-5 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Florbetaben F18 is a F18-labeled stilbene derivative, which binds to beta-amyloid plaques in the brain. The F 18 isotope produces a positron signal that is detected by a PET scanner.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| March 19, 2014 | FDA | PIRAMAL IMAGING |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | V09AX06 | VARIOUS DIAGNOSTIC RADIOPHARMACEUTICALS CENTRAL NERVOUS SYSTEM Other central nervous system diagnostic radiopharmaceuticals |
| FDA MoA | N0000175869 | Positron Emitting Activity |
| FDA EPC | N0000177914 | Radioactive Diagnostic Agent |
| CHEBI has role | CHEBI:37336 | radioactive imaging agent |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Positron emission tomography | indication | 82918005 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 4.51 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.4-135mCi/ML | NEURACEQ | LIFE MOLECULAR | N204677 | March 19, 2014 | RX | SOLUTION | INTRAVENOUS | 7807135 | March 18, 2029 | NEURACEQ IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE P-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Amyloid beta A4 protein | Unclassified | Ki | 8.65 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| TLA7312TOI | UNII |
| C3818757 | UMLSCUI |
| CHEBI:79033 | CHEBI |
| CHEMBL566752 | ChEMBL_ID |
| 11501341 | PUBCHEM_CID |
| DB09148 | DRUGBANK_ID |
| 9184 | INN_ID |
| 1492940 | RXNORM |
| 219505 | MMSL |
| 30276 | MMSL |
| d08254 | MMSL |
| 015462 | NDDF |
| 712736002 | SNOMEDCT_US |
| 717828005 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Neuraceq | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54828-001 | INJECTION, SOLUTION | 135 mCi | INTRAVENOUS | NDA | 19 sections |
| Neuraceq | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54828-001 | INJECTION, SOLUTION | 135 mCi | INTRAVENOUS | NDA | 19 sections |
| Neuraceq | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54828-001 | INJECTION, SOLUTION | 135 mCi | INTRAVENOUS | NDA | 19 sections |